Adagene $25 million strategic equity investment from Sanofi
We advised Adagene on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Medtide HK$411.2 million IPO
We advised Medtide on its IPO and HKEX listing
Mirxes Holding Company HK$1.09 billion IPO
We advised Mirxes on its IPO and HKEX listing
PegBio IPO
We advised PegBio on its IPO and HKEX listing
Visen Pharmaceutical HK$783.3 million IPO
The shares are listed on the HKEX
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing
Laekna HK$236 million placement of shares
We advised Laekna on the placement of new shares
Adagene $100 million at-the-market offering
We advised Adagene on the offering
H&H International CNY500 million bonds offering
The investment-grade notes are due 2027